CL2017002470A1 - Proceso para obtener mezclas de polvo seco - Google Patents

Proceso para obtener mezclas de polvo seco

Info

Publication number
CL2017002470A1
CL2017002470A1 CL2017002470A CL2017002470A CL2017002470A1 CL 2017002470 A1 CL2017002470 A1 CL 2017002470A1 CL 2017002470 A CL2017002470 A CL 2017002470A CL 2017002470 A CL2017002470 A CL 2017002470A CL 2017002470 A1 CL2017002470 A1 CL 2017002470A1
Authority
CL
Chile
Prior art keywords
dry powder
micronized
pharmaceutical
invention refers
powder mixture
Prior art date
Application number
CL2017002470A
Other languages
English (en)
Inventor
Gupta Abbishek
Clark Chiou Herbert
De Samiran
Koppenhagen Franciscus
Zeng Xiang-Ming
Original Assignee
Lupin Atlantis Holdings Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Atlantis Holdings Sa filed Critical Lupin Atlantis Holdings Sa
Publication of CL2017002470A1 publication Critical patent/CL2017002470A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

<p>LA INVENCIÓN SE REFIERE A PROCEDIMIENTOS PARA LA MEZCLA DE POLVO SECO. ESPECÍFICAMENTE, LA INVENCIÓN SE REFIERE A LA MEZCLA DE POLVO SECO DE PARTÍCULAS Y POLVOS SÓLIDOS FARMACÉUTICOS Y NO FARMACÉUTICOS. MÁS ESPECÍFICAMENTE, LA INVENCIÓN SE REFIERE A LA MEZCLA DE POLVO SECO DE MICROPARTÍCULAS, Y A MEZCLAS EN POLVO SECAS PARA USO COMO PRODUCTOS FARMACÉUTICOS. EN PARTICULAR, LA PRESENTE INVENCIÓN SE REFIERE A UN PROCEDIMIENTO PARA PREPARAR UNA MEZCLA EN POLVO DE MICROPARTÍCULAS SECAS QUE COMPRENDE UNO O MÁS INGREDIENTES FARMACÉUTICOS ACTIVOS MICRONIZADOS (API) Y OPCIONALMENTE UNO O MÁS VEHÍCULOS MICRONIZADOS O NO MICRONIZADOS FARMACÉUTICAMENTE ACEPTABLES Y/O EXCIPIENTE(S), EN EL QUE EL PROCEDIMIENTO COMPRENDE LAS ETAPAS DE "MEZCLA PULSANTE" DEL INGREDIENTE(S) FARMACÉUTICO ACTIVO(S) MICRONIZADO(S) Y EL(LOS) VEHÍCULO(S) Y/O EXCIPIENTE(S) FARMACÉUTICAMENTE ACEPTABLE(S).</p>
CL2017002470A 2015-04-01 2017-09-29 Proceso para obtener mezclas de polvo seco CL2017002470A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN380KO2015 2015-04-01

Publications (1)

Publication Number Publication Date
CL2017002470A1 true CL2017002470A1 (es) 2018-04-13

Family

ID=56024334

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002470A CL2017002470A1 (es) 2015-04-01 2017-09-29 Proceso para obtener mezclas de polvo seco

Country Status (14)

Country Link
US (1) US10617646B2 (es)
EP (1) EP3277265A1 (es)
CN (1) CN107864622A (es)
AU (1) AU2016241369A1 (es)
BR (1) BR112017021111A2 (es)
CA (1) CA2981440A1 (es)
CL (1) CL2017002470A1 (es)
CO (1) CO2017011220A2 (es)
EA (1) EA201792159A1 (es)
IL (1) IL254814A0 (es)
MA (1) MA41855A (es)
MD (1) MD20170094A2 (es)
MX (1) MX2017012633A (es)
WO (1) WO2016156970A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019067708A1 (en) * 2017-09-27 2019-04-04 Teva Branded Pharmaceutical Products R&D, Inc. METHOD FOR DECREASING PARTICLE SIZE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0324897D0 (en) 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
US20110105449A1 (en) * 2007-11-07 2011-05-05 Astrazeneca R&D Dry powder formulations comprising ascorbic acid derivates
WO2013091006A1 (en) 2011-12-23 2013-06-27 Monash University Process for dry powder blending
GB201205632D0 (en) 2012-03-30 2012-05-16 Vectura Ltd Method and apparatus
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis

Also Published As

Publication number Publication date
CA2981440A1 (en) 2016-10-06
IL254814A0 (en) 2017-12-31
MD20170094A2 (ro) 2018-04-30
US20180071218A1 (en) 2018-03-15
CO2017011220A2 (es) 2018-01-16
MA41855A (fr) 2021-03-31
AU2016241369A1 (en) 2017-11-02
BR112017021111A2 (pt) 2018-07-03
US10617646B2 (en) 2020-04-14
EA201792159A1 (ru) 2018-01-31
MX2017012633A (es) 2018-06-20
CN107864622A (zh) 2018-03-30
EP3277265A1 (en) 2018-02-07
WO2016156970A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
AR102926A1 (es) Composiciones anticancerosas
BR112019024747A2 (pt) formulações de dose fixa
UY37741A (es) Derivados de indolina sustituidos como inhibidores de la replicación del virus del dengue
CL2017002022A1 (es) Composiciones farmaceuticas que contienen n-(3,5-dimetilfosfeno) - n&#39;-(1-metiletil) - n - [3-(1-metil-1h-pirazol-4-yl) quinoxalina - 6 - yl] etano -1,2 - diamina
EA201791702A1 (ru) Терапевтические средства на основе гликанов и связанные с ними способы
CL2017000782A1 (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación del virus del dengue
ECSP18073264A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue
CL2018002758A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue.
UY36665A (es) Derivados de ciclohexano sustituidos con amidas
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
CL2018003178A1 (es) Composición farmacéutica
DOP2015000005A (es) Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
WO2014118808A3 (en) Ticagrelor solid dispersion
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
EA201790949A1 (ru) Замещенные 2,4-диаминохинолины в качестве новых противораковых средств
IN2013MU03583A (es)
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
MX2017009289A (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.
BR112015010271A8 (pt) produto de comicronização, processo para o preparo de um produto de comicronização, composição farmacêutica e seus usos
WO2015173701A3 (en) Pharmaceutical compositions comprising danirixin for treating infectious diseases
MX2018011696A (es) Composición farmacéutica de dapagliflozina.
MY191712A (en) Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
WO2016005995A3 (en) Glycol free stable liquid compositions of bendamustine
CL2017002470A1 (es) Proceso para obtener mezclas de polvo seco
BR112015020443A2 (pt) desamorfização de formulações secadas por atomização via mistura por atomização